Sofia Ya. Skachilova
Sofia Ya. Skachilova has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Valeryevna Blinova
Sechenov University
5 shared publications - Dmitrii S. Blinov
Dmitry Rogachev National Research Medical Center of Pediatric Hematology, Oncology and Immunology
4 shared publications - Ekaterina A. Simakina
АО «Всесоюзный научный центр по безопасности биологически активных веществ», г. Старая Купавна, Россия
4 shared publications - Viktor Vladimirovich Yasnetsov
All-Union Scientific Center for the Safety of Biologically Active Compounds; State Scientific Center of the Russian Federation — Institute of Biomedical Problems, Russian Academy of Sciences
4 shared publications - Elena V. Shilova
All-Union Scientific Center for the Safety of Biologically Active Substances JSC
3 shared publications - A. Yu. Parshina
National research Mordovia State University named after N. P. Ogarev
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 33 (4) , 45-57
Efficacy of a novel 3-hydroxypyridine derivative in the stabilization of free radical oxidation in post-traumatic osteoarthritis: A randomized preclinical study
Background. While diverse conservative options exist, the prevalence of post-traumatic osteoarthritis remains high. This fact necessitates the search for novel multitarget pathogenetic agents to prevent disease progression and irreversible joint tissue degeneration resulting from delayed treatment. Objective. To evaluate the effect of a novel 3-hydroxypyridine derivative (2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate) on free radical oxidation and antioxidant status in an experimental model of post-traumatic osteoarthritis. Methods. A randomized preclinical study was conducted on 55 outbred white male rats weighing 190–220 g. The rats were divided into five groups: intact animals (Group 1; n = 15) and four groups with induced knee joint injury (Groups 2–5; n = 10 each). Group 2 remained untreated, while Groups 3, 4, and 5 received pharmacotherapy with ibuprofen (6.35 mg/kg), ethylmethylhydroxypyridine succinate (45.58 mg/kg), and 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate (11.65 mg/kg), respectively. Free radical oxidation and antioxidant status were evaluated in plasma and erythrocytes based on biochemiluminescence data, concentrations of primary and secondary lipid peroxidation products, and antioxidant enzyme activity. Statistical analysis of the obtained data was conducted via one-way analysis of variance followed by Tukey’s post hoc test. Calculations were performed using the SPSS Statistics 20.0 software (IBM, USA). Differences were considered statistically significant at p < 0.05. Results. The compound 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate demonstrated the highest efficacy compared to both ethylmethylhydroxypyridine succinate and ibuprofen. The pronounced antioxidant effect of this novel 3-hydroxypyridine derivative was characterized by the stabilization of free radical oxidation by the end of the experiment, with the evaluated parameters approaching reference values. Specifically, compared to the ibuprofen-treated group, the conjugated diene level was 45% lower ( p 2 < 0.001). Similarly, in plasma and erythrocyte samples undergoing spontaneous oxidation, malondialdehyde levels were lower by 35% and 24%, respectively ( p 2 < 0.001). The conjugated diene level in the ethylmethylhydroxypyridine succinate group exceeded that of the novel compound group by 20% ( p 3 < 0.001), while plasma and erythrocyte malondialdehyde levels were higher by 7% ( p 3 = 0.048) and 9% ( p 3 = 0.041), respectively. Furthermore, an increased antioxidant activity was observed in Group 5. The plasma superoxide dismutase activity was 86% greater than in the ibuprofen-treated group ( p 2 < 0.001) and surpassed the group treated with ethylmethylhydroxypyridine succinate by 37% ( p 3 < 0.001). The total chemiluminescence produced was 32% higher than in the ibuprofen-treated group ( p 2 < 0.001) and 12% greater than in the ethylmethylhydroxypyridine succinate group ( p 3 = 0.028), indicating an enhanced antioxidant potential. Conclusion. The novel compound 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate effectively inhibits lipid peroxidation and restores antioxidant enzyme activity. Its administration mitigates free-radical damage to joint tissues and accelerates the restoration of antioxidant potential, both by enhancing the activity of key enzymes and directly lowering free-radical levels. These findings indicate its high predicted efficacy as a pathogenetic agent in the comprehensive management of post-traumatic osteoarthritis.
- 28 August 2026
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 33 (4) , 45-57
Open AccessEfficacy of a novel 3-hydroxypyridine derivative in the stabilization of free radical oxidation in post-traumatic osteoarthritis: A randomized preclinical study
Background. While diverse conservative options exist, the prevalence of post-traumatic osteoarthritis remains high. This fact necessitates the search for novel multitarget pathogenetic agents to prevent disease progression and irreversible joint tissue degeneration resulting from delayed treatment. Objective. To evaluate the effect of a novel 3-hydroxypyridine derivative (2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate) on free radical oxidation and antioxidant status in an experimental model of post-traumatic osteoarthritis. Methods. A randomized preclinical study was conducted on 55 outbred white male rats weighing 190–220 g. The rats were divided into five groups: intact animals (Group 1; n = 15) and four groups with induced knee joint injury (Groups 2–5; n = 10 each). Group 2 remained untreated, while Groups 3, 4, and 5 received pharmacotherapy with ibuprofen (6.35 mg/kg), ethylmethylhydroxypyridine succinate (45.58 mg/kg), and 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate (11.65 mg/kg), respectively. Free radical oxidation and antioxidant status were evaluated in plasma and erythrocytes based on biochemiluminescence data, concentrations of primary and secondary lipid peroxidation products, and antioxidant enzyme activity. Statistical analysis of the obtained data was conducted via one-way analysis of variance followed by Tukey’s post hoc test. Calculations were performed using the SPSS Statistics 20.0 software (IBM, USA). Differences were considered statistically significant at p < 0.05. Results. The compound 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate demonstrated the highest efficacy compared to both ethylmethylhydroxypyridine succinate and ibuprofen. The pronounced antioxidant effect of this novel 3-hydroxypyridine derivative was characterized by the stabilization of free radical oxidation by the end of the experiment, with the evaluated parameters approaching reference values. Specifically, compared to the ibuprofen-treated group, the conjugated diene level was 45% lower ( p 2 < 0.001). Similarly, in plasma and erythrocyte samples undergoing spontaneous oxidation, malondialdehyde levels were lower by 35% and 24%, respectively ( p 2 < 0.001). The conjugated diene level in the ethylmethylhydroxypyridine succinate group exceeded that of the novel compound group by 20% ( p 3 < 0.001), while plasma and erythrocyte malondialdehyde levels were higher by 7% ( p 3 = 0.048) and 9% ( p 3 = 0.041), respectively. Furthermore, an increased antioxidant activity was observed in Group 5. The plasma superoxide dismutase activity was 86% greater than in the ibuprofen-treated group ( p 2 < 0.001) and surpassed the group treated with ethylmethylhydroxypyridine succinate by 37% ( p 3 < 0.001). The total chemiluminescence produced was 32% higher than in the ibuprofen-treated group ( p 2 < 0.001) and 12% greater than in the ethylmethylhydroxypyridine succinate group ( p 3 = 0.028), indicating an enhanced antioxidant potential. Conclusion. The novel compound 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate effectively inhibits lipid peroxidation and restores antioxidant enzyme activity. Its administration mitigates free-radical damage to joint tissues and accelerates the restoration of antioxidant potential, both by enhancing the activity of key enzymes and directly lowering free-radical levels. These findings indicate its high predicted efficacy as a pathogenetic agent in the comprehensive management of post-traumatic osteoarthritis.
- 7 November 2025
- Published by Scientific and Practical Center "Psychosomatic Normalization" in Вестник психофизиологии
- No. 3,p. 45-60
ВЛИЯНИЕ НООТРОПА ДЕАНОЛА АЦЕГЛУМАТА НА ПОВЕДЕНИЕ В ТЕСТАХ НА ТРЕВОЖНОСТЬ У КРЫС ПРИ СТАНДАРТНОМ И СКУЧЕННОМ СОДЕРЖАНИИ
Разработка и внедрение малотоксичных препаратов с естественным для мозга составом для лечения различных неврологических расстройств – важная задача современной нейронауки, психофизиологии и медицины. Один из них - деанола ацеглумат (аптечное название Нооклерин, ПикФарма), состоящий из аналога глутаминовой кислоты и предшественника ацетилхолина и обладающий ноотропной, нейропротективной, антиастенической, антиоксидантной активностью. Данные по анксиолитической активности деанола ацеглумата противоречивы. При психосоциальном стрессе скученности у крыс развивается тревожно-депрессивное поведение. Оказывает ли деанола ацеглумат анксиолитическое воздействие на поведение крыс при скученности, неизвестно. Деанола ацеглумат употребляется в жидкой (20% водный раствор, для перорального и иньекционного введения) и твёрдой (таблетки и капсулы) формах. Для лучшего попадания в мозг широко используется интраназальное введение низкомолекулярных препаратов. В настоящей работе впервые применена разработанная нами форма деанола ацеглумата для интраназального введения, основной особенностью которой является отсутствие вспомогательных веществ, затрудняющих проникновение препарата в мозг. Цель работы – определить, окажет ли деанола ацеглумат при интраназальном введении анксиолитическое воздействие на поведение в тестах на тревожность у крыс при психосоциальном стрессе скученности. Методы. Крысам самцам Вистар в условиях скученности (n=18 в клетке) с 11 по 21 дни вводили по 50 мкл деанола ацеглумата на физиологическом растворе (ФР) (70 мкг/кг) (n=9) или по 50 мкл (ФР) (n=9 ). Крысам при стандартном содержании аналогично вводили деанола ацеглумат (n=9) или ФР (n=9). Поведение крыс по множеству показателей оценивали на 18-20 дни скученности в тестах открытое поле, свет темнота и приподнятый крестообразный лабиринт. Изучали прирост массы тела всех групп крыс в период введения препаратов. Результаты. При скученном содержании у групп крыс как на фоне ФР, так и деанола ацеглумата, прирост массы тела был выше, чем у аналогичных групп при стандартном содержании. Деанола ацеглумат не оказал воздействия на этот показатель при обоих условиях содержания. По совокупности показателей поведения во всех тестах оказалось, что в стандартных условиях у группы крыс, которым вводили деанола ацеглумат, по сравнению с группой, получавшей ФР, уменьшается исследовательская и двигательная активность и увеличивается груминг, что свидетельствует о тревожном поведении. При скученном содержании, по сравнению со стандартным, на фоне введения ФР у крыс снижается исследовательская активность, но увеличивается двигательная активность, число посещений отсеков камер, время посещения светлых рукавов, число актов свешивания, то есть, развивается ажитированное тревожное поведение. Под действием деанола ацеглумата показатели ажитированного поведения крыс при скученности снижаются, и многие из них не отличается от контрольных в стандартных условиях. Таким образом, в стандартных условиях получен анксиогенный эффект деанола ацеглумата при интраназальном введении (в дозе 70 мг/кг) на поведение крыс в тестах на тревожность, тогда как в условиях скученности деанола ацеглумат оказал, наоборот, анксиолитическое воздействие на поведение. Мы предполагаем, что деанола...
- 7 November 2025
- Published by Scientific and Practical Center "Psychosomatic Normalization" in Вестник психофизиологии
- No. 3,p. 45-60
ВЛИЯНИЕ НООТРОПА ДЕАНОЛА АЦЕГЛУМАТА НА ПОВЕДЕНИЕ В ТЕСТАХ НА ТРЕВОЖНОСТЬ У КРЫС ПРИ СТАНДАРТНОМ И СКУЧЕННОМ СОДЕРЖАНИИ
Разработка и внедрение малотоксичных препаратов с естественным для мозга составом для лечения различных неврологических расстройств – важная задача современной нейронауки, психофизиологии и медицины. Один из них - деанола ацеглумат (аптечное название Нооклерин, ПикФарма), состоящий из аналога глутаминовой кислоты и предшественника ацетилхолина и обладающий ноотропной, нейропротективной, антиастенической, антиоксидантной активностью. Данные по анксиолитической активности деанола ацеглумата противоречивы. При психосоциальном стрессе скученности у крыс развивается тревожно-депрессивное поведение. Оказывает ли деанола ацеглумат анксиолитическое воздействие на поведение крыс при скученности, неизвестно. Деанола ацеглумат употребляется в жидкой (20% водный раствор, для перорального и иньекционного введения) и твёрдой (таблетки и капсулы) формах. Для лучшего попадания в мозг широко используется интраназальное введение низкомолекулярных препаратов. В настоящей работе впервые применена разработанная нами форма деанола ацеглумата для интраназального введения, основной особенностью которой является отсутствие вспомогательных веществ, затрудняющих проникновение препарата в мозг. Цель работы – определить, окажет ли деанола ацеглумат при интраназальном введении анксиолитическое воздействие на поведение в тестах на тревожность у крыс при психосоциальном стрессе скученности. Методы. Крысам самцам Вистар в условиях скученности (n=18 в клетке) с 11 по 21 дни вводили по 50 мкл деанола ацеглумата на физиологическом растворе (ФР) (70 мкг/кг) (n=9) или по 50 мкл (ФР) (n=9 ). Крысам при стандартном содержании аналогично вводили деанола ацеглумат (n=9) или ФР (n=9). Поведение крыс по множеству показателей оценивали на 18-20 дни скученности в тестах открытое поле, свет темнота и приподнятый крестообразный лабиринт. Изучали прирост массы тела всех групп крыс в период введения препаратов. Результаты. При скученном содержании у групп крыс как на фоне ФР, так и деанола ацеглумата, прирост массы тела был выше, чем у аналогичных групп при стандартном содержании. Деанола ацеглумат не оказал воздействия на этот показатель при обоих условиях содержания. По совокупности показателей поведения во всех тестах оказалось, что в стандартных условиях у группы крыс, которым вводили деанола ацеглумат, по сравнению с группой, получавшей ФР, уменьшается исследовательская и двигательная активность и увеличивается груминг, что свидетельствует о тревожном поведении. При скученном содержании, по сравнению со стандартным, на фоне введения ФР у крыс снижается исследовательская активность, но увеличивается двигательная активность, число посещений отсеков камер, время посещения светлых рукавов, число актов свешивания, то есть, развивается ажитированное тревожное поведение. Под действием деанола ацеглумата показатели ажитированного поведения крыс при скученности снижаются, и многие из них не отличается от контрольных в стандартных условиях. Таким образом, в стандартных условиях получен анксиогенный эффект деанола ацеглумата при интраназальном введении (в дозе 70 мг/кг) на поведение крыс в тестах на тревожность, тогда как в условиях скученности деанола ацеглумат оказал, наоборот, анксиолитическое воздействие на поведение. Мы предполагаем, что деанола...
- Open Access
- 16 July 2025
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 11 (3) , 61-76
A drug as a two-faced Janus: dose-effect, adverse events
Introduction: In the pharmaceutical industry, the 21st century was marked by the creation of new highly effective drugs: synthetic, immunobiological, genetic engineering, etc. Pharmacotherapy with highly effective drugs leads to a detailed study of their safety and pharmacoepidemiological studies, both in our country and abroad. Materials and Methods: The work used content analysis, monitoring of scientific articles using the databases PubMed, Scopus, Google Scholar, ResearchGate, analysis of the nomenclature of the State Register of Medicines of the Russian Federation (2017-2024) and the Register of Medicines of Russia (2017-2024). Results and Discussion: Adverse drug reactions (ADRs). Adverse drug reactions (ADRs) are diverse in their clinical manifestations, mechanisms of action and frequency of occurrence. The main factors from the use of drugs that cause ADRs and influence on often irreversible complications. Safety of pharmacotherapy when using optically active drugs. Safety of pharmacotherapy when using antioxidants. Pharmacovigilance for monitoring and safety of medicinal products. Conclusion: Irrational pharmacotherapy with highly effective drugs (antioxidants, optically active drugs) without taking into account individual doses leads to errors both by medical personnel and to errors in self-medication especially for the treatment of central nervous system diseases. The problem of safety of pharmacotherapy is solved with the introduction of rational pharmacovigilance and safety monitoring programs.
- 16 July 2025
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 11 (3) , 61-76
Open AccessA drug as a two-faced Janus: dose-effect, adverse events
Introduction: In the pharmaceutical industry, the 21st century was marked by the creation of new highly effective drugs: synthetic, immunobiological, genetic engineering, etc. Pharmacotherapy with highly effective drugs leads to a detailed study of their safety and pharmacoepidemiological studies, both in our country and abroad. Materials and Methods: The work used content analysis, monitoring of scientific articles using the databases PubMed, Scopus, Google Scholar, ResearchGate, analysis of the nomenclature of the State Register of Medicines of the Russian Federation (2017-2024) and the Register of Medicines of Russia (2017-2024). Results and Discussion: Adverse drug reactions (ADRs). Adverse drug reactions (ADRs) are diverse in their clinical manifestations, mechanisms of action and frequency of occurrence. The main factors from the use of drugs that cause ADRs and influence on often irreversible complications. Safety of pharmacotherapy when using optically active drugs. Safety of pharmacotherapy when using antioxidants. Pharmacovigilance for monitoring and safety of medicinal products. Conclusion: Irrational pharmacotherapy with highly effective drugs (antioxidants, optically active drugs) without taking into account individual doses leads to errors both by medical personnel and to errors in self-medication especially for the treatment of central nervous system diseases. The problem of safety of pharmacotherapy is solved with the introduction of rational pharmacovigilance and safety monitoring programs.
- Open Access
- 10 October 2024
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 23 (3) , 74-82
The effect of a new 3-hydroxypyridine derivative LHT-2-20 on free radical oxidation in experimental periodontitis
Aim. To study the effect of a new complex compound LHT-2-20 (2-ethyl-6-methyl-3-hydroxypyridine-2-(3benzoyl phenyl)-propanoate) on free radical oxidation in experimental periodontitis.Materials and methods. The experimental study was performed on 195 white mongrel mice weighing 19–23 g and 137 white mongrel rats weighing 180–220 g. The effect of a new complex compound LHT-2-20 (2-ethyl-6methyl-3-hydroxypyridine-2-(3-benzoyl phenyl)-propanoate) on the intensity of free radical oxidation and the local state of periodontal tissues during a course of intragastric administration was studied on the experimental model of periodontitis. Statistical processing of the results was carried out using the SPSS Statistics 20.0 software package with the analysis of variance (ANOVA) and the parametric Tukey’s test.Results. The LHT-2-20 compound reduced elevated levels of primary and secondary lipoperoxidation products (conjugated dienes, malondialdehyde in plasma and in erythrocytes during spontaneous and iron-induced oxidation) already at the early stages of the experiment, bringing the studied parameters closer to the reference values by the end of the course of treatment. The use of the compound LHT-2-20 contributed to an increase in the activity of the main antioxidant enzymes (catalase and superoxide dismutase), normalizing them to baseline values by the end of the experiment. With the correction of free radical processes, the use of LHT-2-20 limited the local inflammatory response in periodontal tissues, which was confirmed by a decrease in gingival edema and hyperemia, bleeding, depth of periodontal pockets, and tooth mobility.Conclusion. The results of this study confirm the anti-inflammatory potential of the compound and the multiplicity of its effects due to the impact on the mechanisms of oxidative stress. The expediency of further study of the drug is justified by the prospect of creating a new drug and its subsequent wide clinical application as part of the complex therapy of periodontal inflammation.
- 10 October 2024
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 23 (3) , 74-82
Open AccessThe effect of a new 3-hydroxypyridine derivative LHT-2-20 on free radical oxidation in experimental periodontitis
Aim. To study the effect of a new complex compound LHT-2-20 (2-ethyl-6-methyl-3-hydroxypyridine-2-(3benzoyl phenyl)-propanoate) on free radical oxidation in experimental periodontitis.Materials and methods. The experimental study was performed on 195 white mongrel mice weighing 19–23 g and 137 white mongrel rats weighing 180–220 g. The effect of a new complex compound LHT-2-20 (2-ethyl-6methyl-3-hydroxypyridine-2-(3-benzoyl phenyl)-propanoate) on the intensity of free radical oxidation and the local state of periodontal tissues during a course of intragastric administration was studied on the experimental model of periodontitis. Statistical processing of the results was carried out using the SPSS Statistics 20.0 software package with the analysis of variance (ANOVA) and the parametric Tukey’s test.Results. The LHT-2-20 compound reduced elevated levels of primary and secondary lipoperoxidation products (conjugated dienes, malondialdehyde in plasma and in erythrocytes during spontaneous and iron-induced oxidation) already at the early stages of the experiment, bringing the studied parameters closer to the reference values by the end of the course of treatment. The use of the compound LHT-2-20 contributed to an increase in the activity of the main antioxidant enzymes (catalase and superoxide dismutase), normalizing them to baseline values by the end of the experiment. With the correction of free radical processes, the use of LHT-2-20 limited the local inflammatory response in periodontal tissues, which was confirmed by a decrease in gingival edema and hyperemia, bleeding, depth of periodontal pockets, and tooth mobility.Conclusion. The results of this study confirm the anti-inflammatory potential of the compound and the multiplicity of its effects due to the impact on the mechanisms of oxidative stress. The expediency of further study of the drug is justified by the prospect of creating a new drug and its subsequent wide clinical application as part of the complex therapy of periodontal inflammation.
- Open Access
- 31 March 2023
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 86 (3) , 11-16
Влияние новых производных 3-гидроксипиридина на NMDA-индуцированную дегенерацию сетчатки
Глутаматной эксайтотоксичности отводится ключевая роль в нейродегенерации сетчатки. Являясь основным возбуждающим нейромедиатором, глутамат в избыточном количестве провоцирует эксайтотоксичность, приводя к гибели ганглионарных клеток сетчатки. Нами была изучена фармакологическая активность новых соединений, производных 3-гидроксипиридина, под лабораторным шифром ЛХТ 1-21 и ЛХТ 6-20, на модели повреждений сетчатки, вызванных интравитреальным введением N-метил-D-аспартата (NMDA) крысам. Через 7 дней после введения NMDA было выявлено, что наибольшей активностью обладало соединение ЛХТ 6-20. ЛХТ 6-20 в дозе 25,5 мг/кг при внутримышечном введении в течение 7 дней приводит к увеличению уровня микроциркуляции в сетчатке на 48 %, по сравнению с этим показателем у животных, получавших NMDA (p < 0,05); а также увеличению амплитуды α-волны на 37,8 % (p < 0,05), β-волны на 53,7 % (p < 0,05) по сравнению с группой повреждений сетчатки; увеличению количества ядер в ганглионарном слое на 87,7 %, по сравнению с группой NMDA (p < 0,05). Высказано предположение о том, что соединение ЛХТ 6 – 20 оказывает ретинопротективное действие на модели NMDA-индуцированной эксайтотоксичности сетчатки.
- 31 March 2023
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 86 (3) , 11-16
Open AccessВлияние новых производных 3-гидроксипиридина на NMDA-индуцированную дегенерацию сетчатки
Глутаматной эксайтотоксичности отводится ключевая роль в нейродегенерации сетчатки. Являясь основным возбуждающим нейромедиатором, глутамат в избыточном количестве провоцирует эксайтотоксичность, приводя к гибели ганглионарных клеток сетчатки. Нами была изучена фармакологическая активность новых соединений, производных 3-гидроксипиридина, под лабораторным шифром ЛХТ 1-21 и ЛХТ 6-20, на модели повреждений сетчатки, вызванных интравитреальным введением N-метил-D-аспартата (NMDA) крысам. Через 7 дней после введения NMDA было выявлено, что наибольшей активностью обладало соединение ЛХТ 6-20. ЛХТ 6-20 в дозе 25,5 мг/кг при внутримышечном введении в течение 7 дней приводит к увеличению уровня микроциркуляции в сетчатке на 48 %, по сравнению с этим показателем у животных, получавших NMDA (p < 0,05); а также увеличению амплитуды α-волны на 37,8 % (p < 0,05), β-волны на 53,7 % (p < 0,05) по сравнению с группой повреждений сетчатки; увеличению количества ядер в ганглионарном слое на 87,7 %, по сравнению с группой NMDA (p < 0,05). Высказано предположение о том, что соединение ЛХТ 6 – 20 оказывает ретинопротективное действие на модели NMDA-индуцированной эксайтотоксичности сетчатки.
- Open Access
- 26 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 12953
Novel Hydroxypyridine Compound Protects Brain Cells against Ischemic Damage In Vitro and In Vivo
A non-surgical pharmacological approach to control cellular vitality and functionality during ischemic and/or reperfusion-induced phases of strokes remains extremely important. The synthesis of 2-ethyl-6-methyl-3-hydroxypyridinium gammalactone-2,3-dehydro-L-gulonate (3-EA) was performed using a topochemical reaction. The cell-protective effects of 3-EA were studied on a model of glutamate excitotoxicity (GluTox) and glucose-oxygen deprivation (OGD) in a culture of NMRI mice cortical cells. Ca2+ dynamics was studied using fluorescent bioimaging and a Fura-2 probe, cell viability was assessed using cytochemical staining with propidium iodide, and gene expression was assessed by a real-time polymerase chain reaction. The compound anti-ischemic efficacy in vivo was evaluated on a model of irreversible middle cerebral artery (MCA) occlusion in Sprague-Dawley male rats. Brain morphological changes and antioxidant capacity were assessed one week after the pathology onset. The severity of neurological disorder was evaluated dynamically. 3-EA suppressed cortical cell death in a dose-dependent manner under the excitotoxic effect of glutamate and ischemia/reoxygenation. Pre-incubation of cerebral cortex cells with 10–100 µM 3-EA led to significant stagnation in Ca2+ concentration in a cytosol ([Ca2+]i) of neurons and astrocytes suffering GluTox and OGD. Decreasing intracellular Ca2+ and establishing a lower [Ca2+]i baseline inhibited necrotic cell death in an acute experiment. The mechanism of 3-EA cytoprotective action involved changes in the baseline and ischemia/reoxygenation-induced expression of genes encoding anti-apoptotic proteins and proteins of the oxidative status; this led to inhibition of the late irreversible stages of apoptosis. Incubation of brain cortex cells with 3-EA induced an overexpression of the anti-apoptotic genes BCL-2, STAT3, and SOCS3, whereas the expression of genes regulating necrosis and inflammation (TRAIL, MLKL, Cas-1, Cas-3, IL-1β and TNFa) were suppressed. 3-EA 18.0 mg/kg intravenous daily administration for 7 days following MCA occlusion preserved rats’ cortex neuron population, decreased the severity of neurological deficit, and spared antioxidant capacity of damaged tissues. 3-EA demonstrated proven short-term anti-ischemic activity in vivo and in vitro, which can be associated with antioxidant activity and the ability to target necrotic and apoptotic death. The compound may be considered a potential neuroprotective molecule for further pre-clinical investigation.
- 26 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 12953
Open AccessNovel Hydroxypyridine Compound Protects Brain Cells against Ischemic Damage In Vitro and In Vivo
A non-surgical pharmacological approach to control cellular vitality and functionality during ischemic and/or reperfusion-induced phases of strokes remains extremely important. The synthesis of 2-ethyl-6-methyl-3-hydroxypyridinium gammalactone-2,3-dehydro-L-gulonate (3-EA) was performed using a topochemical reaction. The cell-protective effects of 3-EA were studied on a model of glutamate excitotoxicity (GluTox) and glucose-oxygen deprivation (OGD) in a culture of NMRI mice cortical cells. Ca2+ dynamics was studied using fluorescent bioimaging and a Fura-2 probe, cell viability was assessed using cytochemical staining with propidium iodide, and gene expression was assessed by a real-time polymerase chain reaction. The compound anti-ischemic efficacy in vivo was evaluated on a model of irreversible middle cerebral artery (MCA) occlusion in Sprague-Dawley male rats. Brain morphological changes and antioxidant capacity were assessed one week after the pathology onset. The severity of neurological disorder was evaluated dynamically. 3-EA suppressed cortical cell death in a dose-dependent manner under the excitotoxic effect of glutamate and ischemia/reoxygenation. Pre-incubation of cerebral cortex cells with 10–100 µM 3-EA led to significant stagnation in Ca2+ concentration in a cytosol ([Ca2+]i) of neurons and astrocytes suffering GluTox and OGD. Decreasing intracellular Ca2+ and establishing a lower [Ca2+]i baseline inhibited necrotic cell death in an acute experiment. The mechanism of 3-EA cytoprotective action involved changes in the baseline and ischemia/reoxygenation-induced expression of genes encoding anti-apoptotic proteins and proteins of the oxidative status; this led to inhibition of the late irreversible stages of apoptosis. Incubation of brain cortex cells with 3-EA induced an overexpression of the anti-apoptotic genes BCL-2, STAT3, and SOCS3, whereas the expression of genes regulating necrosis and inflammation (TRAIL, MLKL, Cas-1, Cas-3, IL-1β and TNFa) were suppressed. 3-EA 18.0 mg/kg intravenous daily administration for 7 days following MCA occlusion preserved rats’ cortex neuron population, decreased the severity of neurological deficit, and spared antioxidant capacity of damaged tissues. 3-EA demonstrated proven short-term anti-ischemic activity in vivo and in vitro, which can be associated with antioxidant activity and the ability to target necrotic and apoptotic death. The compound may be considered a potential neuroprotective molecule for further pre-clinical investigation.
- 19 September 2022
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
NON-EXPERIMENTAL SEARCH FOR MOLECULES WITH ANTITUMOR ACTIVITY AND MOLECULAR DOCKING IN THE SERIES OF PYRIDINECARBOXY ACID DERIVATIVES
In the work, a pre-experimental screening of pyridinecarboxylic acid derivatives was performed by the PASS program, The work identified potential molecular targets for the implementation of the antitumor effect of a new domestic compound, an analogue of pyridine LHT-13-19. Using the "Autodock 4.2" software environment, flexible receptor-directed molecular biological docking was carried out in virtual reality, which makes it possible to most accurately predict the formation of a complex between a molecular structure and a biological target in real conditions of a specific biological system. For molecular docking, three-dimensional structures of the epidermal growth factor receptor (EGFR, PDB ID: 1M17, 4KN2) from the open electronic library Protein Data Bank (USA) were used. Molecules of compounds - pyridine derivatives LHT-13-19, LHT-16-19 and LHT-17-19 were synthesized in the Department of Chemistry, All-Union Research Center for Biological Active Compounds Safety (Russia). As a result of the experiments, it was found that all the studied molecules have inhibitory activity against proto-oncogenic kinases, however, in terms of the totality of predictive characteristics, as well as the likelihood of forming an antitumor effect, LHT-17-19, which was studied in docking studies, turned out to be the most promising compound. It was shown that LHT-17-19 has a high affinity for the epidermal growth factor kinase receptor EGFR-K, exhibits an affinity for the CSF1 receptor system, superior to that of all comparators - imatinib, erlotinib and pemetrexed. Also, in the process of docking approach and subsequent docking with the active site of tyrosine kinase EGFR-K and the human folate receptor FOLR2, an additional hydrogen bond is formed inside the LHT-17-19 molecule between the hydrogen proton of the amino group and the oxygen atom of the carbonyl group with atomic distances of 2.21 Å and 2 .49 Å, respectively.
- 19 September 2022
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
NON-EXPERIMENTAL SEARCH FOR MOLECULES WITH ANTITUMOR ACTIVITY AND MOLECULAR DOCKING IN THE SERIES OF PYRIDINECARBOXY ACID DERIVATIVES
In the work, a pre-experimental screening of pyridinecarboxylic acid derivatives was performed by the PASS program, The work identified potential molecular targets for the implementation of the antitumor effect of a new domestic compound, an analogue of pyridine LHT-13-19. Using the "Autodock 4.2" software environment, flexible receptor-directed molecular biological docking was carried out in virtual reality, which makes it possible to most accurately predict the formation of a complex between a molecular structure and a biological target in real conditions of a specific biological system. For molecular docking, three-dimensional structures of the epidermal growth factor receptor (EGFR, PDB ID: 1M17, 4KN2) from the open electronic library Protein Data Bank (USA) were used. Molecules of compounds - pyridine derivatives LHT-13-19, LHT-16-19 and LHT-17-19 were synthesized in the Department of Chemistry, All-Union Research Center for Biological Active Compounds Safety (Russia). As a result of the experiments, it was found that all the studied molecules have inhibitory activity against proto-oncogenic kinases, however, in terms of the totality of predictive characteristics, as well as the likelihood of forming an antitumor effect, LHT-17-19, which was studied in docking studies, turned out to be the most promising compound. It was shown that LHT-17-19 has a high affinity for the epidermal growth factor kinase receptor EGFR-K, exhibits an affinity for the CSF1 receptor system, superior to that of all comparators - imatinib, erlotinib and pemetrexed. Also, in the process of docking approach and subsequent docking with the active site of tyrosine kinase EGFR-K and the human folate receptor FOLR2, an additional hydrogen bond is formed inside the LHT-17-19 molecule between the hydrogen proton of the amino group and the oxygen atom of the carbonyl group with atomic distances of 2.21 Å and 2 .49 Å, respectively.
- Open Access
- 13 September 2022
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 8 (3) , 81-86
Antitumor activity of the novel pyridine derivative
Introduction: The study aim was to explore a toxicological property and antitumor action of the novel pyridine derivative LHT-17-19 in cell culture and on experimental models of lung cancer in mice. Materials and methods: The study was performed on male and female ICR(CD-1), male BALB/c, male BALB/c nu/nu mice. Pyridine derivative (LHT-17-19) was studied as water-soluble pharmaceutical substance. Acute toxicity was evaluated in groups of 5 animals, and the results were analyzed by Finney. Antitumor and antimetastatic activity was studied in syngeneic and xenograft models of lung cancer in mice. Results and discussion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with GOST 12.1.007–76. The substance demonstrated an antitumor and antimetastatic property in mice with syngeneic tumor Lewis lung carcinoma as well as on the heterotopic tumor model of non-small cell lung cancer in humanized animals. Conclusion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with WHO recommendation. LHT-17-19 exerts antitumor and antimetastatic property on both syngeneic and patient-derived lung cancer xenograft murine models. Graphical
- 13 September 2022
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 8 (3) , 81-86
Open AccessAntitumor activity of the novel pyridine derivative
Introduction: The study aim was to explore a toxicological property and antitumor action of the novel pyridine derivative LHT-17-19 in cell culture and on experimental models of lung cancer in mice. Materials and methods: The study was performed on male and female ICR(CD-1), male BALB/c, male BALB/c nu/nu mice. Pyridine derivative (LHT-17-19) was studied as water-soluble pharmaceutical substance. Acute toxicity was evaluated in groups of 5 animals, and the results were analyzed by Finney. Antitumor and antimetastatic activity was studied in syngeneic and xenograft models of lung cancer in mice. Results and discussion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with GOST 12.1.007–76. The substance demonstrated an antitumor and antimetastatic property in mice with syngeneic tumor Lewis lung carcinoma as well as on the heterotopic tumor model of non-small cell lung cancer in humanized animals. Conclusion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with WHO recommendation. LHT-17-19 exerts antitumor and antimetastatic property on both syngeneic and patient-derived lung cancer xenograft murine models. Graphical
- Open Access
- 24 April 2022
- Published by LLC MAKS Press
- p. 310-311
ANTIOXIDANTS ARE INEXHAUSTIBLE AS AN ELECTRON. STRUCTURE – ACTIVITY
- 24 April 2022
- Published by LLC MAKS Press
- p. 310-311
Open AccessANTIOXIDANTS ARE INEXHAUSTIBLE AS AN ELECTRON. STRUCTURE – ACTIVITY
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Operative Surgery and Clinical Anatomy
- Vol. 6 (3)
Experimental postoperative skin wound healing after Z-grafting followed by local application of cerium-containing N-acetyl-6-aminohexanoic acid compound
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить косметический эффект, прочность рубца и время заживления послеоперационной раны кожи при Z-образной пластике на фоне локального воздействия формы в виде спрея церийсодержащего соединения N-ацетил-6-аминогексановой кислоты в эксперименте. МАТЕРИАЛ И МЕТОДЫ Z-образную пластику кожи в области холки встречными лоскутами проводили 18 белым лабораторным крысам линии Vistar и 9 минипигам. Все животные были разделены на три группы: 1-я группа — контроль, животные 2-й группы получали препарат сравнения пантенол на область раны, 3-й группы — церийсодержащее соединение N-ацетил-6-аминогексановой кислоты (ЛХТ-8-17) в форме спрея. На 3, 7, 14 и 21-е сутки оценивали косметический эффект по шкале SCAR и время заживления кожной раны. Прочность сформировавшегося рубца на разрыв изучали после завершения эксперимента. РЕЗУЛЬТАТЫ Местное применение ЛХТ-8-17 в форме спрея сокращает время заживления операционной раны при Z-образной пластике на 17±13 сут по сравнению с контролем (p=0,03), на 27% (p=0,04) увеличивает прочность рубца у крыс и на 17% (p=0,04) — у минипигов, улучшает косметические характеристики сформировавшегося рубца на 21-е сутки эксперимента. ЗАКЛЮЧЕНИЕ В исследовании показана эффективность применения спрея церийсодержащего соединения N-ацетил-6-аминогексановой кислоты при Z-образной пластике кожи, характеризующаяся сокращением сроков заживления послеоперационной раны, улучшением прочностных и косметических характеристик рубцовой ткани.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Operative Surgery and Clinical Anatomy
- Vol. 6 (3)
Experimental postoperative skin wound healing after Z-grafting followed by local application of cerium-containing N-acetyl-6-aminohexanoic acid compound
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить косметический эффект, прочность рубца и время заживления послеоперационной раны кожи при Z-образной пластике на фоне локального воздействия формы в виде спрея церийсодержащего соединения N-ацетил-6-аминогексановой кислоты в эксперименте. МАТЕРИАЛ И МЕТОДЫ Z-образную пластику кожи в области холки встречными лоскутами проводили 18 белым лабораторным крысам линии Vistar и 9 минипигам. Все животные были разделены на три группы: 1-я группа — контроль, животные 2-й группы получали препарат сравнения пантенол на область раны, 3-й группы — церийсодержащее соединение N-ацетил-6-аминогексановой кислоты (ЛХТ-8-17) в форме спрея. На 3, 7, 14 и 21-е сутки оценивали косметический эффект по шкале SCAR и время заживления кожной раны. Прочность сформировавшегося рубца на разрыв изучали после завершения эксперимента. РЕЗУЛЬТАТЫ Местное применение ЛХТ-8-17 в форме спрея сокращает время заживления операционной раны при Z-образной пластике на 17±13 сут по сравнению с контролем (p=0,03), на 27% (p=0,04) увеличивает прочность рубца у крыс и на 17% (p=0,04) — у минипигов, улучшает косметические характеристики сформировавшегося рубца на 21-е сутки эксперимента. ЗАКЛЮЧЕНИЕ В исследовании показана эффективность применения спрея церийсодержащего соединения N-ацетил-6-аминогексановой кислоты при Z-образной пластике кожи, характеризующаяся сокращением сроков заживления послеоперационной раны, улучшением прочностных и косметических характеристик рубцовой ткани.